Literature DB >> 14644200

Epithelial-mesenchymal transitions in development and pathologies.

Jean Paul Thiery1.   

Abstract

The epithelial-mesenchymal transition (EMT) is a fundamental process governing morphogenesis in multicellular organisms. This process is also reactivated in a variety of diseases including fibrosis and in the progression of carcinoma. The molecular mechanisms of EMT were primarily studied in epithelial cell lines, leading to the discovery of transduction pathways involved in the loss of epithelial cell polarity and the acquisition of a variety of mesenchymal phenotypic traits. Similar mechanisms have also been uncovered in vivo in different species, showing that EMT is controlled by remarkably well-conserved mechanisms. Current studies further emphasise the critical importance of EMT and provide a better molecular and functional definition of mesenchymal cells and how they emerged >500 million years ago as a key event in evolution.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14644200     DOI: 10.1016/j.ceb.2003.10.006

Source DB:  PubMed          Journal:  Curr Opin Cell Biol        ISSN: 0955-0674            Impact factor:   8.382


  646 in total

Review 1.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Authors:  A Singh; J Settleman
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

Review 2.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

3.  S100A4 silencing blocks invasive ability of esophageal squamous cell carcinoma cells.

Authors:  Dong Chen; Xue-Feng Zheng; Ze-You Yang; Dong-Xiao Liu; Guo-You Zhang; Xue-Long Jiao; Hui Zhao
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

4.  NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression.

Authors:  Margit A Huber; Ninel Azoitei; Bernd Baumann; Stefan Grünert; Andreas Sommer; Hubert Pehamberger; Norbert Kraut; Hartmut Beug; Thomas Wirth
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

Review 5.  Targeting stroma to treat cancers.

Authors:  Boris Engels; Donald A Rowley; Hans Schreiber
Journal:  Semin Cancer Biol       Date:  2011-12-24       Impact factor: 15.707

6.  Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines.

Authors:  Wei Zhang; Michael Peyton; Yang Xie; Junichi Soh; John D Minna; Adi F Gazdar; Eugene P Frenkel
Journal:  J Thorac Oncol       Date:  2009-02       Impact factor: 15.609

7.  Protrusive activity guides changes in cell-cell tension during epithelial cell scattering.

Authors:  Venkat Maruthamuthu; Margaret L Gardel
Journal:  Biophys J       Date:  2014-08-05       Impact factor: 4.033

8.  Paclitaxel inhibits ovarian tumor growth by inducing epithelial cancer cells to benign fibroblast-like cells.

Authors:  Lizhou Jia; Shiwu Zhang; Yanfen Ye; Xin Li; Imelda Mercado-Uribe; Robert C Bast; Jinsong Liu
Journal:  Cancer Lett       Date:  2012-08-15       Impact factor: 8.679

Review 9.  Invasion and metastasis of renal cell carcinoma.

Authors:  Shuji Mikami; Mototsugu Oya; Ryuichi Mizuno; Takeo Kosaka; Ken-ichi Katsube; Yasunori Okada
Journal:  Med Mol Morphol       Date:  2013-11-09       Impact factor: 2.309

10.  TGF-β regulation of gene expression at early and late stages of HPV16-mediated transformation of human keratinocytes.

Authors:  Sangeeta Kowli; Rupa Velidandla; Kim E Creek; Lucia Pirisi
Journal:  Virology       Date:  2013-09-19       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.